NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosa<
24 Jan 2024

SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosa

Positive recommendation received from the Data Safety Monitoring Board (DSMB) enabling progression to highest dose of Part 1 of the PRODYGY trial
Synendos Therapeutics AG Granted EMA Clinical Trial Authorisation for first-in-class Endocannabinoid System modulator, SYT-510<
18 Jan 2024

Synendos Therapeutics AG Granted EMA Clinical Trial Authorisation for first-in-class Endocannabinoid System modulator, SYT-510

1. Synendos Therapeutics transitions to a clinical-stage biotech company developing innovative Endocannabinoid System

Am-Pharma initiates Phase 2 trial of Ilofotase Alfa for Cardiac Surgery-Associated Renal Damage<
16 Jan 2024

Am-Pharma initiates Phase 2 trial of Ilofotase Alfa for Cardiac Surgery-Associated Renal Damage

Trial will evaluate ilofotase alfa as a treatment to prevent renal damage in at-risk patients following open heart surgery
Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer<
04 Jan 2024

Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer

Dr. Kim brings more than two decades of experience in business development, strategic leadership, and scientific research
Kynexis Announces Initiation of First-in-Human Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia<
04 Jan 2024

Kynexis Announces Initiation of First-in-Human Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia

Topline results are expected in the second half of 2024
SpliceBio Appoints Leading Ophthalmology Expert Aniz Girach as Chief Medical Officer Retinal Disease<
03 Jan 2024

SpliceBio Appoints Leading Ophthalmology Expert Aniz Girach as Chief Medical Officer Retinal Disease

Appointment further strengthens SpliceBio’s leadership team as it accelerates lead program targeting Stargardt disease towards clinical development
Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension<
21 Dec 2023

Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension

Topline data from ongoing Advance-HTN pivotal trial expected in 2H 2024
Biocytogen Enters into Antibody Agreement with Ona Therapeutics to Develop Antibody-Drug Conjugates Targeting Solid Tumors<
18 Dec 2023

Biocytogen Enters into Antibody Agreement with Ona Therapeutics to Develop Antibody-Drug Conjugates Targeting Solid Tumors

Under the terms of the agreement, Biocytogen will grant Ona access to evaluate Biocytogen’s proprietary RenMice®-derived fully human antibodies against a specific tumor target.
Inbiomotion and The Scientific Group sign an exclusive distribution agreement of MAF Test® for the Sub-Saharan Africa<
13 Dec 2023

Inbiomotion and The Scientific Group sign an exclusive distribution agreement of MAF Test® for the Sub-Saharan Africa

MAF Test® will benefit an estimated 10,200 new patients each year just in South Africa
CorWave announces the appointment of Fairuz Hasni as Vice President Human Resources<
05 Dec 2023

CorWave announces the appointment of Fairuz Hasni as Vice President Human Resources

Fairuz Hasni has over twenty years of experience in industrial companies.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.